SK Capital Has Entered Into Exclusive Negotiations to Acquire LISI Group’s Medical Division
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”).
The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, the transaction is expected to close in the second half of 2025.
Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implants. Lisi Medical operates four manufacturing sites with expertise in precision machining, forging, and engineering solutions, including highly automated production – two in Minnesota, U.S. and two in France.
Josh Lieberman, Principal at SK Capital, commented, “We feel privileged to partner with LISI Group to acquire Lisi Medical, whose deep engineering heritage and cutting-edge manufacturing technologies enable it to serve as a critical solutions provider for the world’s largest MedTech OEM customers. Under LISI Group’s ownership, the Company has made significant investments to increase automation, expand production capacity, and add capabilities to support the growth of its customers. We look forward to working with Lisi Medical’s management team to accelerate the Company’s growth by expanding with existing and new customers and continuing to add new capabilities both organically and through M&A.”
Aaron Davenport, Managing Director at SK Capital, added, “Given Lisi Medical’s highly engineered solutions and deep relationships with leading MedTech customers, the Company fits very well within the SK Capital portfolio. SK Capital has deep experience in the life sciences CDMO sector and a long-standing track record of carving out businesses and establishing them as thriving, independent platforms, and we believe Lisi Medical represents an attractive opportunity to implement our transformational growth strategy.”
Emmanuel Viellard, CEO of LISI Group, stated, “After 14 years of strong development and manufacturing consolidation within LISI Group, we are now looking forward to partner with SK Capital and boost Lisi Medical’s next development phase. Their strong track record in the life sciences sector and proven experience in France provide the essential strategic foresight and financial power to support the company going forward. This will also empower Lisi Medical to expand its offerings and capabilities, while solidifying its standing as a top-tier partner for leading MedTech OEMs. We are confident this transaction will be beneficial to all stakeholders of Lisi Medical, be it employees, clients or suppliers.”
Kirkland & Ellis is serving as legal counsel and Piper Sandler & Co., Jefferies LLC, and Sycomore Corporate Finance are serving as financial advisors to SK Capital. Partners Group, acting on behalf of its clients, provided committed debt financing in support of the transaction.
Rothschild & Co is serving as financial advisor and Dentons is serving as legal counsel to LISI Group.
About SK Capital
SK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.
About the LISI Group
LISI is a global industrial group specialising in the manufacture of high value-added assembly solutions and components for the aerospace, automotive and medical sectors. As a partner to the world's leading players and driven by its long-standing family values, LISI innovates and invests in research and development for the products of tomorrow. to meet its customers' needs, particularly in terms of quality, safety and performance. The LISI Group thus sets itself apart by relying on two strategic pillars: innovation and operational excellence, while integrating a strong CSR culture. Learn more at www.lisi-group.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250709076615/en/
Contacts
Jeremy Milner
Gregory FCA
jmilner@gregoryfca.com
(401) 862-9422
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 21:36:00 CET | Press Release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
Picsart and Zazzle Power the Creator-to-Commerce Evolution with Print-On-Demand Integration17.12.2025 20:47:00 CET | Press Release
Picsart, the world’s leading digital creation platform with over two billion downloads and more than 100 million monthly active users, is partnering with Zazzle, the global leader in customized products and designs, to deliver an end-to-end printing solution for Picsart users. The new “vibe-design-to-print” integration works seamlessly with Picsart’s recently expanded suite of AI products, including AI Assistant and Flows, enabling creators to ideate, iterate, design, and bring their work to life as physical art and products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217882832/en/ Picsart and Zazzle Power the Creator-to-Commerce Evolution with Print-On-Demand Integration “At Picsart, our mission has always been to give creators the tools they need to bring their ideas to life,” said Hovhannes Avoyan, Founder and CEO of Picsart. “As we enter what we believe will be the year of the creative entrepreneur, creators are i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom